Ledger.Open graph →
SEC Form D · Amendment · filed January 9, 2013

Revance Therapeutics, Inc

Offering
$63.4M
Sold
$63.4M
Exemption
Industry
Pharmaceuticals
Location
NEWARK, CA
Type

People & firms on this filing (16)

Robert Byrnes · Newark, CADirectorFrank Kung · Newark, CADirectorVicente Trelles · Newark, CADirectorPhyllis Gardner · Newark, CADirectorJim Glasheen · Newark, CADirectorJonathan Tunnicliffe · Newark, CADirectorL. D. Browne · Newark, CAExec · DirectorRon Eastman · Newark, CADirectorJoel R. Beaudin · North River, NYExec · DirectorDan Beecroft · Boca Raton, FLDirectorBlake Beecroft · Boca Raton, FLDirectorToney Jennings · Austin, TXDirectorDaniel M. Teal · Austin, TXDirectorRichard Teal · Austin, TXDirectorGregory J. Petro · Pittsburgh, PADirectorJan Steenbrugge · Boston, MADirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗